Immune intratumoral microenvironment differences between sexes in colorectal tumors

Colorectal cancer is a disease that does not treat men and women the same way. For decades, doctors and scientists have noticed that men are more likely to develop this type of cancer and often face a harder battle against it than women. While lifestyle choices like diet and smoking play a role, they do not tell the whole story. There is something deeper at work, rooted in the biological differences between the sexes. The immune system, the body's internal defense force, operates differently in men and women. Generally, women mount a stronger and more aggressive response to threats, while men often have a more subdued reaction. This study set out to look inside the tumors themselves to see how these immune defenses behave differently in male and female mice, hoping to uncover why the disease progresses more aggressively in one sex than the other.

Researchers used a well-established method to create colorectal tumors in mice, a process that mimics the way chronic inflammation can lead to cancer in humans. They treated both male and female mice with a chemical that damages the lining of the colon, followed by cycles of a substance that causes inflammation. This combination reliably triggers the growth of tumors. Once the tumors had developed, the team examined the mice to see what was happening on the surface and deep within the tissue. At a glance, the difference was clear: the male mice had far more tumors, and those tumors were significantly larger than those found in the females. But the researchers wanted to know more than just size and number; they needed to understand the quality of the damage and the cellular environment surrounding the growth.

When they looked at the tissue under a microscope, the story became even more specific. The tumors in the male mice were not just bigger; they were also more dangerous in their structure. The male mice developed a higher number of lesions with a finger-like shape, known as villous lesions, which are known to carry a higher risk of turning into aggressive cancer. Furthermore, the male tumors showed a much higher rate of adenocarcinoma, the most common and serious form of colorectal cancer. In contrast, the tumors in the female mice were less severe in their structure. This confirmed that the biological sex of the host influences not only how many tumors form but also how aggressive and dangerous they become.

To understand why this happens, the team peered into the microscopic world inside the tumors, counting the different types of immune cells that had gathered there. They found a distinct pattern in the male mice. Their tumors were crowded with macrophages, a type of immune cell that, in this context, seemed to be helping the cancer grow rather than fighting it. These cells were drawn to the tumor by a specific chemical signal, a messenger molecule called CCL-2, which was found in high concentrations in the male mice. The researchers also noted an increase in a specific type of T cell, known as gamma-delta T cells, in the male tumors. While these cells can sometimes help fight cancer, their presence here, alongside the macrophages and the high levels of CCL-2, suggested a environment that was supporting the tumor's expansion.

The female mice told a different story. Their tumors were filled with a different kind of immune army. Instead of the pro-tumor cells seen in males, the female tumors were heavily infiltrated by cytotoxic lymphocytes, which are cells trained to seek out and destroy abnormal cells. The females also had higher numbers of B cells and plasma cells, which are responsible for producing antibodies and coordinating a targeted attack against the cancer. This robust presence of cells designed to eliminate the threat suggests that the female immune system was mounting a more effective defense, keeping the tumor burden lower and the tissue damage less severe.

The differences were not limited to the tumor site itself. When the researchers looked at the rest of the body, specifically the spleen and the lymph nodes near the gut, they found that the systemic immune landscape also varied by sex. The male mice had higher levels of the chemical messenger CCL-2 circulating in their blood, mirroring what was happening inside the tumor. They also had higher levels of another inflammatory molecule, IL-1 beta. In the spleen, the female mice showed lower levels of certain immune cells compared to the males, but this seemed to be part of a different strategy, perhaps conserving resources for the specific battle at the tumor site. The data suggests that the entire body of the male mouse is in a state that favors tumor growth, while the female body maintains a posture that is more hostile to the cancer.

These findings point to a clear conclusion: the biological sex of the patient fundamentally shapes the environment in which colorectal cancer grows. In the male mice, the immune system appears to be inadvertently aiding the cancer through the recruitment of cells and chemicals that support tumor growth. In the female mice, the immune system is more actively engaged in fighting the disease. This research highlights that treating colorectal cancer cannot be a one-size-fits-all approach. Understanding these deep biological differences could help doctors develop treatments that work better for men by targeting the specific immune pathways that are currently helping their tumors thrive, while also leveraging the natural strengths seen in the female response to improve outcomes for everyone.